Cancer Supportive Care Market By Cancer (Lung Cancer, Liver Cancer, Breast Cancer, Leukemia, Prostate Cancer, Ovarian Cancer, Bladder Cancer), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), By Therapeutic Area (Oral Mucositis And Dry Mouth, Chemotherapy Induced Nausea And Vomiting Cancer Pain, Chemotherapy Induced Anemia, Chemotherapy Induced Neutropenia, Bone Metastases) - Growth, Future Prospects And Competitive Analysis, 2016 - 2024

Supportive care is a high importance area in cancer care and management. Prevention of radiotherapy and chemotherapy induced anemia, management of mucosal injury, treatment of dyspnea, management of cancer pain, venous thromboembolism, bone metastases, cardiovascular toxicity and others hold a critical significance and specific guidelines have been established for delivering best cancer treatment outcomes.

This report titled “Cancer Supportive Care Market - Growth, Future Prospects and Competitive Analysis, 2016 – 2024” is to offer industry investors, company executives, and industry participants with in depth insights to enable them make informed strategic decisions related to the opportunities in the cancer supportive care drugs market. The major target audience of this study include industry investors, cancer drugs manufacturers, distributors, and institutional scholars.

This study classifies the global cancer supportive care market into type therapeutics, cancer types, sales channels and geographical distribution. Based on therapeutic types, the overall market is studied for Oral Mucositis and Dry Mouth, Chemotherapy Induced Nausea and Vomiting, Cancer Pain, Chemotherapy Induced Anemia, Chemotherapy Induced Neutropenia and Bone Metastases. Lung Cancer, Liver Cancer, Breast Cancer, Leukemia, Prostate Cancer, Ovarian Cancer, Bladder Cancer and cancers are the major oncology areas for which the cancer supportive care market is studied. The sales channels considered for distribution of cancer supportive care drugs are hospital pharmacies, retail pharmacies and compounding pharmacies. Market size and forecast for each mentioned segment are provided in this report for the period 2013-2024 (US$ Mn), along with respective CAGR (value %) for the period 2016-2024.

Geographically, the global cancer supportive care market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Market size and respective forecast for these regional and country level markets are presented in this study for the period 2013-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cancer supportive care market. Tools such as market positioning of key players, and attractive investment proposition provide the readers with insights on the competitive scenario of the global cancer supportive care market. This report concludes with company profiles section that highlights major information about the key players engaged in development, manufacture and sales of cancer supportive care drugs.

Cancer Supportive Care Market

Based on the therapeutic areas, the global cancer supportive care market is segmented as follows:

  • Oral Mucositis and Dry Mouth
  • Chemotherapy Induced Nausea and Vomiting
  • Cancer Pain
  • Chemotherapy Induced Anemia
  • Chemotherapy Induced Neutropenia
  • Bone Metastases

Cancer Supportive Care Market

Supportive care interventions can assist in preventing or minimizing the adverse effects of cancer treatments, across all phases of cancer management. Though associated pain is the largest addressable area in supportive care regimen, chemotherapy induced anemia and chemotherapy induced neutropenia together claim the largest market segment in the overall cancer supportive care market. Drugs such as erythropoietin stimulating agents are largely used for hematological management during cancer treatments. Other therapeutic areas such as chemotherapy induced nausea and vomiting also attract significant focus with several innovative CINV drugs being rapidly adopted across geographies. The ageing global population is rapidly leading to geriatric cancer patients. For this group of patients, supportive care is critically important to augment survival and clinical outcomes. Providers of supportive care products are engaged in severe race to maintain their share and stronghold in the market, particularly with the steady advancement of life-extending cancer medications. However such treatment drugs are observed to be significantly expensive, particularly in the developing economies, where the reach of reimbursements still lags when compared to Western Europe and North America. This phenomenon will support the mainstay and further steady progress of cancer supportive drugs market in developing countries of Asia and Middle East and Africa. 

For the purpose of this study, the global cancer supportive care market is categorized as follows:

  • North America (U.S., Canada)
  • Europe (U.K., Germany, Rest of Europe)
  • Asia Pacific (Japan, China, Australia, Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East and Africa (Saudi Arabia, South Africa, Rest of MEA)

Cancer Supportive Care Market

North America and Europe are the largest markets for cancer supportive care drugs. Huge population base and corresponding patient pool are the chief contributors to the dominance of Asia Pacific on the global front. It is anticipated that North America and Western Europe will witness moderate yet steady growth through the forecast period. The fastest market growth will be observed in Asia Pacific on the ground of significant population and corresponding patient pool, rising prevalence of cancer in the region and swift development of healthcare infrastructure. Government initiatives, growing commercialization of new supportive care drugs and rising adoption of direct-to-consumer marketing are predicted to be the key trends in the developed markets. Further clarity in reimbursement policies will open new opportunities for drug manufacturers in this market.

Choose License Type
Published Date:  Dec 2016
Category:  Pharmaceuticals
Report ID:   58293
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Connect With Us
24/7 Research Support